Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lymphoma
Biotech
Viracta axes staff to slim down for race to cancer finish line
Viracta responded to phase 2 data by throwing its resources behind a bid to a plan to file for a blood cancer approval in 2026.
Nick Paul Taylor
Aug 14, 2024 8:09am
FDA blocks approval of Regeneron's blood cancer drug
Mar 25, 2024 9:25pm
Innate drops monotherapy plans for lacutamab in type of lymphoma
Mar 21, 2024 8:27am
Allogene stops pivotal trials, pursues first-line CAR-T cures
Jan 5, 2024 8:55am
Innate secures speedy resolution of FDA hold on lymphoma trials
Jan 4, 2024 9:50am
Kymera cuts lymphoma med that performed as expected in phase 1
Nov 2, 2023 9:30am